Comment on Optimal Treatment for Resistant Hypertension: The Missing Data on Pulse Wave Velocity

To the Editor:

In Hypertension (October), Egan et al1 provide a new definition of treatment-resistant hypertension and compare treatment with ≤2 versus ≥3 classes of antihypertensive agents for uncontrolled and controlled hypertensive individuals. We focus on the uncontrolled group in which blood pressure (BP) was lower with fewer drugs.

Diastolic BP and systolic BP were higher for the ≥3 (systolic BP=151.2; diastolic BP=83.7) than for the ≤2 drug group (systolic BP=149.0; diastolic BP=86.3; n=102.951 in 2 large samples: n=44.686; n=102.951). Egan et al1 speculated that pulse wave velocity (PWV) values (the gold standard for indirect assessment of arterial stiffness) would be higher for the ≥3 drug group, but did not present data on PWV. We provide the missing data.

At the seventh wave of our community-based Maine Syracuse Longitudinal Study (MSLS),2 PWV data were obtained for the first time using the SphygmoCor system and procedure.3 At each wave, subjects were referred back to their physician for between-wave treatment for hypertension and other cardiovascular disease risk factors.4 At each of these, 46% had uncontrolled BP (>140 systolic BP and/or >90 diastolic BP). As in Egan et al,1 the controlled individuals exhibited lower BP and lower PWV values.4 The question we raise is whether higher PWV would be observed for ≥3 classes of antihypertensive medications as compared with ≤2 classes of medications (including a diuretic).

Our BP findings (Table) are consistent with that of Egan et al,1 and we find that PWV was higher in the group taking ≥3 classes of antihypertensive drugs, an association that was sustained when we adjusted age, education, sex, ethnicity, body mass index, diabetes mellitus, and total cholesterol: categorical regression coefficient (b=1.63; SE=0.055; P<0.01). We replicated these findings when the Egan et al1 requirement that a diuretic be included in drug combinations was dropped, ≤2 (n=155) ≥3 (n=66).

We confirm Egan et al1 with our small sample and data on PWV. These data reinforce the concern for effective management of hypertension in polypharmacy, including literature-based choice of drugs and improved patient education and adherence.1,5 This analysis was approved by the University of Maine Institutional Review Board.

Disclosures

None.

Merrill F. Elias
Kevin J. Sullivan
Department of Psychology
University of Maine
Orono


Table. SBP, DBP (mm Hg), and PWV (m/s) for ≤2 and ≥3 Drug Classes Used in Treatment With Egan et al1 Drug Count Included

<table>
<thead>
<tr>
<th>Drug Classes Including Diuretic</th>
<th>≤2</th>
<th>≥3</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSLS, n</td>
<td>48</td>
<td>46</td>
</tr>
<tr>
<td>MSLS med count*</td>
<td>1.69 (1.55–1.82)</td>
<td>3.35 (3.18–3.52)</td>
</tr>
<tr>
<td>Egan et al med count</td>
<td>1.53 (1.53–1.54)</td>
<td>3.76 (3.75–3.77)</td>
</tr>
<tr>
<td>Egan et al age, y</td>
<td>55.9 (55.8–56.0)</td>
<td>60.6 (60.5–60.7)</td>
</tr>
<tr>
<td>MSLS age, y</td>
<td>63.9 (60.5–67.2)</td>
<td>67.0 (63.7–70.8)</td>
</tr>
<tr>
<td>MSLS mean SBP**</td>
<td>141.3 (136.5–145.9)</td>
<td>152.2 (146.6–157.7)</td>
</tr>
<tr>
<td>MSLS mean DBP†</td>
<td>85.9 (83.9–88)</td>
<td>84.7 (82.1–87.2)</td>
</tr>
<tr>
<td>MSLS PWV*</td>
<td>10.3 (9.6–10.6)</td>
<td>12.9 (11.9–13.9)</td>
</tr>
</tbody>
</table>

Data presented are mean values with 95% confidence intervals. BP indicates blood pressure; DBP, diastolic BP; med, medication; MSLS, Maine Syracuse Longitudinal Study; PWV, pulse wave velocity; and SBP, systolic BP.

*Significant difference between ≤2 and ≥3 drug groups in MSLS at P<0.01 was obtained.

†BP measures are based on 15 assessments at wave 7.

Letters to the Editor will be published, if suitable, as space permits. They should not exceed 500 words (typed double-spaced) plus 5 references in length and may be subject to editing or abridgment.

DOI: 10.1161/HYPERTENSIONAHA.113.02742
Comment on Optimal Treatment for Resistant Hypertension: The Missing Data on Pulse Wave Velocity
Merrill F. Elias and Kevin J. Sullivan

_Hypertension._ 2014;63:e16; originally published online February 3, 2014;
doi: 10.1161/HYPERTENSIONAHA.113.02742

_Hypertension_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/63/3/e16

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Hypertension_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Hypertension_ is online at:
http://hyper.ahajournals.org//subscriptions/